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Abstract 54 
 55 
Μinimal invasive extracorporeal circulation (MiECC) systems have initiated 56 
important efforts within science and technology to further improve the 57 
biocompatibility of cardiopulmonary bypass components to minimize the adverse 58 
effects and improve end-organ protection. The Minimal invasive Extra-Corporeal 59 
Technologies international Society (MiECTiS) was founded to create an international 60 
forum for the exchange of ideas on clinical application and research of Minimal 61 
invasive Extra-Corporeal Circulation technology. The present work is a consensus 62 
document developed to standardize the terminology and the definition of minimal 63 
invasive extracorporeal circulation technology as well as to provide recommendations 64 
for the clinical practice. The goal of this manuscript is to promote the use of MiECC 65 
systems into clinical practice as a multidisciplinary strategy involving cardiac 66 
surgeons, anaesthesiologists and perfusionists.  67 
 68 
 69 
 70 
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Introduction 75 
Substantial experience has been accumulated with cardiac procedures performed 76 
using extracorporeal circulation (ECC) over the last decades. Several technological 77 
improvements have been realized, thus making cardiopulmonary bypass (CPB) the 78 
gold standard equipment for the majority of cardiac surgical procedures. This has 79 
contributed to improved perioperative and long-term results, despite an increasing 80 
prevalence of elderly and high-risk patients [1]. For the most frequent procedure, 81 
coronary artery bypass grafting (CABG), CPB provides optimal conditions (bloodless 82 
field and arrested heart) to allow the most complete myocardial revascularization and 83 
additionally offers for the possibility to perform other procedures such as valve repair 84 
or replacement, aortic surgery [2].  85 
Major drawbacks of CPB are the adverse systemic effects triggered by a 86 
systemic inflammatory response syndrome (SIRS), which is mainly caused by the 87 
contact of blood with air and foreign surfaces [3,4]. Trials have shown that the 88 
inflammatory response to CPB adversely influences clinical outcome [5,6] although 89 
CPB cannot be considered as the main cause of postoperative morbidity. 90 
Since the begin of extracorporeal perfusion, the main inputs have been focused 91 
on one objective – to reduce the adverse effects of CPB. Perfusionists and 92 
bioengineers have developed optimized ‘CPB systems’ that combined the best features 93 
derived from perfusion science. The idea was to create a system that integrates all 94 
modifications into one combined set-up, known as the minimal invasive 95 
extracorporeal circulation (MiECC) system [7]. This concept has further initiated 96 
important new efforts to improve the biocompatibility of CPB components and 97 
minimize the side-effects. 98 
Despite clinical advantages that have been reported in several papers [8], 99 
penetration of MiECC technology into clinical practice remains extremely low. There 100 
is also significant heterogeneity between the various systems. Low implementation of 101 
MiECC may be due to the inability to precise which aspects of MiECC are beneficial, 102 
because several elements may act both interactively and/or independently, e.g. coated 103 
surfaces, closed systems, anticoagulation strategies, shed blood separation and reduced 104 
priming volumes.  105 
The Minimal invasive Extra-Corporeal Technologies international Society 106 
(MiECTiS) was founded to create an international forum to exchange ideas on clinical 107 
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practice and research in the field of Minimal invasive Extra-Corporeal Circulation 108 
technology (www.miectis.org). The Society brings together, under a scientific 109 
interdisciplinary association, cardiac surgeons, anaesthesiologists, perfusionists and 110 
basic researchers.  111 
The present work is a consensus document developed to standardize the 112 
terminology around minimal invasive extracorporeal circulation technology and to 113 
provide recommendations for clinical practice. The authors have graded the levels of 114 
evidence and classified the findings listed below using the criteria recommended by 115 
the American Heart Association and the American College of Cardiology Task Force 116 
on Practice Guidelines (Table 1). The authors represent a multidisciplinary group to 117 
promote evidence-based perfusion practice to improve clinical outcomes.   118 
 119 
Methods  120 
The initiative to analyze the current practice was based on a questionnaire which 121 
was written by the Steering Committee of MiECTiS (KA, TC, AB, JM, MR, EG, JS). 122 
During an Expert Consensus Meeting, the statements were discussed and subsequently 123 
this consensus paper was developed. For each statement, the best available published 124 
evidence derived from meta-analyses of peer-reviewed literature, randomized 125 
controlled trials (RCTs) and data coming from large cohort studies were considered. 126 
Relevant studies were searched in PubMed (1975 - present), Embase (January 1980 - 127 
present) and Cochrane review of aggregate data for reports written in any language. 128 
The full PubMed search strategy is available in Table 2 (appendix). Moreover, hand or 129 
computerized search involving the recent (1999-2014) conference proceedings from 130 
the Society of Thoracic Surgeons, European Association for Cardiothoracic Surgery 131 
and European Society for Cardiovascular Surgery and the American Association for 132 
Thoracic Surgery annual meetings was performed; ClinicalTrials.gov was explored in 133 
order to identify any ongoing or unpublished trials (Table 3). 134 
 135 
 136 
  137 
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Recommendations and evidence-based practice guidelines  138 
Expert Committee statements are presented in Table 4. Evidence-based clinical 139 
practice guidelines are presented in Table 5. 140 
 141 
Terminology 142 
 143 
Minimal invasive extracorporeal circulation (MiECC) refers to a combined strategy 144 
of surgical approach, anaesthesiological and perfusion management and is not be 145 
limited to the CPB circuit alone.  146 
Several terms have been used to describe a minimal invasive extracorporeal 147 
circulation circuit: miniaturized extracorporeal circulation (MECC), mini 148 
extracorporeal circulation (mECC), minimized extracorporeal circulation, mini 149 
cardiopulmonary bypass (mCPB, mini-CPB), minimal invasive cardiopulmonary 150 
bypass (MICPB), miniaturized cardiopulmonary bypass (MCPB), veno-arterial 151 
extracorporeal membrane oxygenation, minimized perfusion circuit, minimized 152 
extracorporeal life support system, minimized cardiopulmonary bypass, minimal 153 
invasive extracorporeal circulation. This divergent terminology creates confusion and 154 
disagreement between centres. But the major problem is the fact that the focus is made 155 
only on the priming volume of the circuit and not on the reduction of the adverse 156 
effects of ECC.  157 
The Steering Committee of MiECTiS considers the term ‘minimal invasive’ as a 158 
procedure which involves not only the CPB circuit, but the global approach to the 159 
procedure. This concept strives to render the procedure minimally invasive as opposed 160 
to the widely employed misnomer ‘minimal invasive’ when a limited surgical access is 161 
performed. The term ‘minimal invasive’ is misleading since the patient is often a 162 
longer period on CPB, cross-clamping and duration of the anaesthesia are prolonged. 163 
In this sense, the term minimal invasive relates only to the size of the scar [9]. Hence, 164 
we believe that the term ‘minimal invasive extracorporeal circulation’ corresponds 165 
better to the above mentioned concept and should be used to describe this technology 166 
with the abbreviation: MiECC. 167 
 168 
 169 
  170 
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Components of MiECC system 171 
 172 
In order to be characterized as MiECC, the main components of the system must 173 
include: a closed CPB circuit; biologically inert blood contact surfaces; reduced 174 
priming volume; a centrifugal pump; a membrane oxygenator; a heat exchanger; a 175 
cardioplegia system; a venous bubble trap/venous air removing device and a shed 176 
blood management system.    177 
     178 
Because different groups have utilized either commercially available or 179 
customized CPB circuits with a variety of components, the Consensus Meeting 180 
defined the main components of the CPB circuit when it should correspond to a 181 
MiECC system. The Steering Committee of MiECTiS emphasizes that a MiECC 182 
system should comprise all necessary elements to obtain a maximal benefit.  183 
Originally, MiECC system was an Extracorporeal Life Support (ECLS) circuit 184 
with the possibility to administrate cardioplegia (type I) and used mainly to perform 185 
CABG procedures [10]. However, safety concerns regarding air entrapment / air lock 186 
into the venous line prompted the integration of venous bubble trap/venous air 187 
removing devices into the system (type II). This design increased safety for CABG 188 
procedures and enabled aortic valve surgery [11]. The need for blood volume 189 
management during valvular procedures required the addition of a soft-bag / soft-shell 190 
reservoir integrated into the system (type III). This enabled safe performance of aortic 191 
valve surgery and other intracardiac procedures. Initiation of modular MiECC (hybrid) 192 
systems that integrate a second open circuit with a venous reservoir and cardiotomy 193 
suction as a stand-by component (type IV) enabled performance of complex 194 
procedures that pertain a high possibility of unexpected perfusion scenario [12,13]. 195 
Classification of MiECC types is illustrated in Figure 1. The Consensus Meeting 196 
defined as a prerequisite for a system to be considered as MiECC to have at least type 197 
II circuit characteristics.  198 
Additional components to be integrated into a MiECC system are: 1) pulmonary 199 
artery vent, 2) aortic root vent, 3) pulmonary vein vent, 4) soft bag / soft-shell 200 
reservoir, 5) hard-shell reservoir (modular systems), 6) regulated smart suction device, 201 
7) arterial line filtration.  202 
 203 
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Modular systems 204 
 The major reticence to limit expansion of MiECC is due to thoughts about 205 
safety in case of massive air entrance into the system or significant blood loss. 206 
Although CABG and valve surgery are feasible with the standard type II MiECC 207 
circuit, a modular configuration is welcome to expand MiECC for the majority of 208 
cardiac procedures and to create a ‘safety net’ for unexpected intraoperative scenarios. 209 
Recently published results from a single-centre indicate that a modular circuit design 210 
offers 100% technical success rate in high-risk patients, even in those undergoing 211 
complex procedures including reoperations, valve and aortic surgery as well as 212 
emergency cases [12]. 213 
 214 
Anticoagulation management 215 
 216 
During perfusion with MiECC, less thrombin generation may allow reduced 217 
heparin dose targeted by shorter ACT (Class of Recommendation IIB, Level of 218 
Evidence B). In this case, individual heparin dosage should be determined using 219 
heparin dose-response monitoring systems.  220 
A number of factors including better biocompatible surfaces, elimination of 221 
blood-air interaction and exclusion of unprocessed shed-blood re-infusion favourably 222 
influence thrombin generation under MiECC system compared to the standard CPB 223 
[14]. A patient-adjusted and/or a procedure-adjusted coagulation management based 224 
on unfractionated heparin (UFH) can be adopted [15,16,17]. Thus, a low-dose 225 
anticoagulation protocol for CABG with a targeted activated clotting time (ACT) of 226 
300-350 sec, and 400-450 sec for valve surgery and complex cardiac procedures is 227 
safe [18]. Serial assessment of ACT during CPB is mandatory. Point-of-care (POC) 228 
coagulation monitoring (for instance the Hepcon system) to optimize heparin and 229 
protamine dosage during CPB) is recommended if a low-dose heparin protocol is 230 
adopted. Appropriate protamine reversal should be used post-CPB to normalize ACT. 231 
Continuous infusion of UFH may result in less consumptive coagulopathy and 232 
transfusion requirements [19,20].  233 
 234 
  235 
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Anaesthesia for surgery on MiECC 236 
Use of short-acting opioids in combination with propofol or volatile anaesthetics, 237 
and monitoring of the depth of anaesthesia by processed EEG, is recommended for 238 
all patients undergoing cardiac surgery with MiECC. (Class of Recommendation 239 
IIB, Level of Evidence C). TEE findings pertinent to institutional management of 240 
MiECC should be communicated during the preoperative surgical safety time out 241 
(Class of Recommendation IIB, Level of Evidence C). 242 
Anaesthetic management of patients undergoing cardiac surgery with the aid of a 243 
MiECC system follows the international recommendations, especially regarding the 244 
use of transesophageal echocardiography (TEE) [21,22]. Following anaesthesia 245 
induction, TEE may provide additional information that may influence the site and/or 246 
the type of cannulation or perfusion strategy (eg. patent foramen ovale, significant 247 
mitral or aortic valve pathology or severe aortic atheromatosis). This information is 248 
important when type I or II MiECC systems are used, whereas any modifications can 249 
be accommodated when type III or modular type IV configuration are available.  250 
Specifically, the absence of venous reservoir in MiECC systems renders the 251 
patient´s own venous capacitance compartment critical for haemodynamic as well as 252 
for optimal volume management. Positioning of the patient (Trendelenburg or anti-253 
Trendelenburg) and low-dose vasoactive agents are useful to control intraoperative 254 
haemodynamics. Excessive fluid administration should be avoided to reduce 255 
haemodilution and avoid transfusion [16].  256 
Beneficial effects of MiECC include attenuation of inflammatory response, 257 
higher haematocrit, less coagulation disorders and improved end-organ function 258 
(brain, kidneys, lungs). It facilitates implementation of fast track protocols [23]. 259 
Hence, perioperative use of short-acting intravenous and/or volatile anaesthetic agents 260 
is recommended. Moreover, titration of anaesthetic agents using processed 261 
electroencephalogram (EEG) ensures adequate anaesthesia depth [24]. Microporous 262 
capillary membrane oxygenators enable volatile anaesthetics to be used for anaesthesia 263 
maintenance, which is not feasible with diffusion membrane oxygenators [25]. To date 264 
randomized controlled trials comparing different anaesthetic protocols for MiECC-265 
based surgery are still missing. 266 
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Haemodilution – Haematocrit – Transfusion  267 
MiECC systems reduce haemodilution, better preserve haematocrit and reduce 268 
postoperative bleeding and the need for RBC transfusion (Class of Recommendation 269 
I, Level of Evidence A). 270 
There is compelling evidence that MiECC – mainly because of the significantly 271 
reduced priming volume of the circuit - reduces haemodilution and results in a higher 272 
haematocrit at the end of the perfusion period [26,27]. This significantly reduces need 273 
for red blood cells (RBC) transfusion and improves oxygen delivery during perfusion 274 
[13,18, 26,28,29]. Coagulation disorders are reduced [26] and platelet count and 275 
function are better preserved following perfusion with MiECC systems [30]. 276 
Postoperative bleeding and incidence of re-exploration are significantly lower in 277 
patients operated with MiECC [18]. As it reduces haemodilution, MiECC fulfil, Class 278 
I, Level of Evidence A indication for blood conservation according to the STS 279 
guidelines, especially in patients at high-risk for adverse effects of haemodilution 280 
(paediatric patients and small-sized adults) [8]. Patients refusing transfusion of 281 
allogeneic blood products, e.g. Jehovah’s Witnesses, are optimal candidates for this 282 
strategy [31].  283 
 284 
Attenuation of the inflammatory response 285 
Inflammatory response is attenuated with use of MiECC (Class of Recommendation 286 
IIA, Level of Evidence B) 287 
Several studies have investigated the inflammatory response triggered 288 
conventional CPB and compared it with MiECC systems. MiECC components are 289 
designed to limit the severity of SIRS. Coating and reduction of the size of the circuit 290 
reduce the amount of foreign surfaces, which is the main trigger of SIRS, but   291 
multicenter studies still have to confirm this observation [32]. Assessment of the 292 
inflammatory response is complex and clinical presentation is highly variable [33]. 293 
Nevertheless, some studies provide evidence of the beneficial effects of MiECC. 294 
Moreover, Fromes described a less pronounced intraoperative decrease of monocytes 295 
as well as during the first 24 hours in patients with MiECC than in those with 296 
conventional CPB [34]. Others demonstrated significantly lower peak levels of IL-6 297 
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under MiECC [34-36]. Finally several studies demonstrated that perfusion with 298 
MiECC resulted in significantly lower levels of neutrophil elastase – a specific marker 299 
of neutrophile activation – than with conventional CPB [34,37,38]. 300 
 301 
Neurologic function 302 
MiECC systems reduce cerebral gaseous microembolism and better preserves 303 
neurocognitive function (Class of Recommendation IIA, Level of Evidence B).  304 
Several prospective studies and meta-analyses have reported reduced incidence 305 
of stroke following MiECC when compared to conventional CPB [28,39,40]. A recent 306 
meta-analysis found a trend to reduction of neurologic damage in favour of MiECC 307 
[18]. Of course, stroke is multifactorial and the perfusion system is only one of the 308 
issues beside aortic manipulations and other patient’s specific factors [41]. A possible 309 
explanation for the neuroprotective effect of MiECC is the significant reduction of 310 
gaseous microemboli [42-46]. MiECC also offers improved cerebral perfusion during 311 
CPB, as indicated by the lower reduction in near infrared spectroscopy (NIRS) - 312 
derived regional cerebral oxygen saturation (rScO2) values and cerebral desaturation 313 
episodes [42,45,47,48]. Reduced incidence of cerebral desaturation episodes 314 
favourably affects neurocognitive outcome [49-51]. 315 
 316 
Atrial fibrillation 317 
MiECC reduces the incidence of postoperative atrial fibrillation (Class of 318 
Recommendation I, Level of Evidence A). 319 
Several randomized studies have demonstrated that postoperative atrial 320 
fibrillation (AF) is significantly reduced following MiECC when compared to 321 
conventional CPB [13,23,36,52]. Moreover, there is strong evidence of a lower 322 
incidence of AF in all meta-analyses regarding MiECC systems [18,28,40]. Attenuated 323 
inflammatory reaction and less volume shifts associated with MiECC may be an 324 
explanation for this beneficial effect [53]. 325 
 326 
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Renal function 327 
MiECC preserves renal function (Class of Recommendation I, Level of Evidence A). 328 
Several studies have shown that the use of MiECC systems was associated with 329 
better preservation of renal function [54-56]. This was confirmed by a meta-analysis of 330 
24 RCTs but this meta-analysis and other studies failed to demonstrate a reduced 331 
incidence of postoperative renal failure [18,54,57]. More stable haemodynamic 332 
together with higher perfusion pressure and a reduced need for vasopressors during 333 
MiECC perfusion may explain this observation [10,58]. A significant independent 334 
association was found between the lowest haematocrit value during bypass and acute 335 
renal injury, with significant benefits on renal function seen after reduction of the 336 
priming volume. This may be due to a higher DO2 associated with a higher 337 
haematocrit on CPB [29]. In addition, different markers to evaluate renal function (i.e. 338 
glomerular filtration rate, levels of neutrophil gelatinase-associated lipocalin), confirm 339 
better renal protection under MiECC. Larger studies are required to investigate if this 340 
protective effect is sufficient to prevent development of acute renal failure. 341 
 342 
Myocardial protection 343 
MiECC is associated with improved myocardial protection (Class of 344 
Recommendation I, Level of Evidence A). 345 
Several studies have demonstrated a beneficial effect of MiECC on 346 
intraoperative myocardial protection [10,18,59,60]. Reduced cardioplegia volumes 347 
with less crystalloids and attenuation of SIRS may explain this beneficial effect [34]. 348 
Studies with MiECC and intermittent cross-clamping show a similar effect on 349 
myocardial protection [61]. However, myocardial protection is not related only to the 350 
duration of ischemia, but also to the reperfusion phase. Increased arterial pressure 351 
during CPB as well as the volume-constant perfusion with a closed system may also 352 
contribute to improved myocardial protection [54,58]. 353 
 354 
 355 
  356 
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End-organ protection 357 
MiECC has a subclinical protective effect on end-organ function (lung, liver, 358 
intestine) caused by improved microvascular organ perfusion (Class of 359 
Recommendation IIA, Level of Evidence B).   360 
MiECC is a closed system that allows a better peripheral perfusion with higher 361 
arterial pressure and systemic vascular resistance close to normal values [54]. This is 362 
associated with reduced requirement for vasoactive support [10,58]. Data from 363 
randomized studies suggest improved lung protection [62], attenuated liver and 364 
intestinal dysfunction [55,62,63]. These studies evaluated only surrogate markers of 365 
end-organ dysfunction that may beneficiate from MiECC, while the effects remain 366 
subclinical. However, it may become clinically perceptible in high-risk patients and in 367 
those with longer procedures since MiECC would lead to fewer alterations of 368 
microperfusion [64]. 369 
 370 
Mortality  371 
MiECC appears to offer survival benefit in terms of lower 30-day mortality after 372 
CABG procedures (Class of Recommendation IIB, Level of Evidence B). 373 
A number of studies have demonstrated a trend towards reduced mortality in 374 
CABG performed on MiECC. A recent meta-analysis of 24 studies involving 2770 375 
patients showed that MiECC was associated with a significant decrease in mortality, 376 
compared to conventional CPB (0.5% vs. 1.7%; p=0.02) [18]. This finding has also 377 
confirmed by other studies [65,66,67]. A trend towards decreased mortality in favour 378 
of MiECC has also been found in meta-analyses [28,40] and in a propensity score 379 
analysis [68]. This survival benefit may be the result of the cumulative beneficial 380 
effects of MiECC on end-organ protection but it calls for a multicentre randomized 381 
controlled trial sufficiently powered to prospectively investigate this survival benefit. 382 
 383 
  384 
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Cost-effectiveness 385 
Data from a cost-analysis study indicate a cost-effectiveness of MiECC systems 386 
that offer economic advantages in various healthcare settings [69]. Nevertheless, these 387 
results have to be considered in the context of the local conditions. A more detailed 388 
analysis together with an analysis from payers’ perspective is necessary. Better 389 
standardization should be achieved to allow comparison of costs and economical 390 
benefits. 391 
 392 
 393 
Discussion 394 
MiECC systems have been developed to integrate all advances in CPB 395 
technology in one closed circuit: the goal is to improve biocompatibility and minimize 396 
side-effects of CPB. MiECC is associated with more stable hemodynamic during and 397 
early after perfusion and better end-organ protection. This concept provides 398 
comparable or better outcomes in terms of morbidity and mortality in CABG and 399 
valve procedures, as shown in prospective randomized studies and meta-analyses. 400 
However, despite several clinical advantages, implementation of MiECC technology 401 
remains weak probably there are still some concerns regarding air handling as well as 402 
blood and volume management during perfusion [12]. This Consensus paper primarily 403 
serves to summarize the available information about this technology and to clarify 404 
some of the open issues. We have made substantial efforts to provide the best 405 
available actual evidence and strongly encourage to consider the technology as a 406 
multidisciplinary strategy.   407 
There is still debate about the optimal handling of air during the perfusion, as 408 
well as volume and blood management when a MiECC system is used. Mean arterial 409 
pressure (MAP) is usually higher during MiECC: this raises the question of optimal 410 
pump flow rate during MiECC perfusion [10,58]. A reference blood flow based on 411 
body surface area is not a guarantee of adequate body perfusion during CPB. Modern 412 
protocols adjust pump flow to achieve adequate DO2. In this area, it is still unclear if 413 
the use of MiECC may allow lower than traditional cardiac index without end-organ 414 
damage as has been suggested by recent studies [70,71]. The use of NIRS and other 415 
parameters to monitor cerebral blood flow may lead to greater individualization of 416 
perfusion index for adequate end-organ perfusion [48,72]. Lower heparin requirement 417 
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and reduced haemodilution offered by MiECC facilitate the management of 418 
postoperative bleeding. Prophylactic use of low-dose antifibrinolytics [73] and POC 419 
coagulation management based on thromboelastometry and aggregometry is generally 420 
advised [74]. In patients with higher perioperative risk [68], those with low ejection 421 
fraction and emergencies [67,68,75], MiECC has proven to be safe. 422 
In general, MiECC can be considered as the ‘circuit-of-choice’ to replace 423 
conventional CPB at least for CABG surgery. Novel modular systems (type IV 424 
MiECC) may be utilized for all cardiac procedures. We believe that the terms ‘circuit’ 425 
which refers to the CPB, the ‘MiECC system’ which integrates certain components to 426 
a CPB circuit, and the ‘MiECC strategy’ that represents the multidisciplinary approach 427 
to MiECC should be differentiated. The Minimal invasive Extra-Corporeal 428 
Technologies international Society (MiECTiS) advocates this strategy to obtain the 429 
maximal benefits for the patients. The authors believe that MiECC should be 430 
understood as an additional tool in the chapter of minimal invasiveness. The latter 431 
should not be restricted to ‘minimal-access’ surgery, but should also incorporate a 432 
strategy towards a ‘more physiologic CPB’. Use of MiECC should be integrated 433 
within fast-track algorithms, POC management of coagulation disorders together with 434 
any initiative that improve aortic assessment (epiaortic ultrasound), novel anti-435 
inflammatory strategies, low shear-stress cannula design and implementation of 436 
contemporary biofiltration techniques.  437 
Lack of high volume data requires the creation of a registry to further evaluate 438 
this technology. Moreover, the variation in extent of miniaturisation / complexity of 439 
MiECC systems should be analyzed. Additional RCTs, focusing on valve and other 440 
cardiac procedures, as well as large cohorts of patients will provide more evidence 441 
regarding clinical effectiveness. Adequately powered multicentre studies are required 442 
in order to prove superiority of the MiECC over the conventional CPB. 443 
Concerns in the literature have been raised regarding loss of safety net, 444 
ventricular dilatation during perfusion using the standard circuit, loss of a bloodless 445 
field and the risk of air embolism [76,77]; however, these reports are anecdotal and are 446 
not supported by large-scale studies. Loss of safety during perfusion with a modern 447 
MiECC circuit is easily addressed with integration of a venous bubble trap/air 448 
removing device into the circuit. Moreover, significant air entrainment that blocks the 449 
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circuit could be resolved immediately by a skilled perfusionist. Ventricular dilatation, 450 
attributed to poor off-loading of the heart, is anticipated with the use of aortic root 451 
and/or pulmonary artery/vein venting from type II MiECC onwards. The same applies 452 
to creation of a full bloodless field. Special patient populations, such as patients with a 453 
higher body surface area requiring higher circulatory flows, are easily managed with 454 
kinetic-assisted venous drainage and increased flow through the centrifugal pump. 455 
Regarding air embolism, contemporary evidence suggests that there is significantly 456 
reduced amount of gaseous microemboli in the arterial line of MiECC systems 457 
compared with conventional CPB [78].  458 
Nevertheless, it should be emphasized that MiECC is a demanding system which 459 
should be implemented in cardiac surgery as a strategy and not as a simple circuit. A 460 
real teamwork from all disciplines of the surgical team, meticulous surgery, a skilful 461 
perfusionist and optimal anaesthetic management are mandatory towards a more 462 
physiologic perfusion that could lead to improved clinical outcomes. MiECTiS 463 
supports initiatives that promote research and clinical application of MiECC systems 464 
as a strategy through multidisciplinary training programs (dry labs/hands-on 465 
simulators, wet labs, peer-to-peer workshops). Integration of specific training 466 
programs under the accreditation of MiECTiS will stimulate and improve the 467 
collaboration between clinicians while the industry will get important information to 468 
further improve the systems. MiECTiS is planning to endorse a comprehensive and 469 
structured program that contributes to the advancement of patient care.  470 
In conclusion, the authors consider MiECC as a physiologically-based strategy 471 
and not just a CPB circuit or a particular product. For this reason multidisciplinary 472 
approach is mandatory. Collaboration between surgeons, anaesthesiologists and 473 
perfusionists is of paramount importance to emphasize the key tenets of MiECTiS.  474 
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Figure 1.  728 
 729 
Classification of MiECC circuits [12]. [Note that the modular type IV circuit is 730 
literally type III with a standing-by component, used only when necessary]. 731 
(X:pump; O:oxygenator; C: cardioplegia; T: bubble-trap/air removing device; V: vent 732 
(aortic/pulmonary); S: soft-bag/reservoir; H:  hard-shell/reservoir).  733 
  734 
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Tables 735 
Table 1. Methodology and policy from the American College of Cardiology/American 736 
Heart Association Task Force on Practice Guidelines. 737 
 738 
Classification of recommendations Level of Evidence 
Class I: Conditions for which there is 
evidence, general agreement, or both that 
a given procedure or treatment is useful 
and effective 
 
Level A: Data derived from multiple 
randomized clinical trials or meta analyses 
Class II: Procedure-treatment should be 
performed-administered 
Level B: Data derived from a single 
randomized trial or nonrandomized 
studies 
Class IIA: Additional studies with focused 
objective needed 
 
Class IIB: Additional studies with broad 
objective needed; additional registry data 
would be helpful 
 
Level C: Consensus opinion of experts 
Class III: Procedure-treatment should not 
be performed-administered because it is 
not helpful or might be harmful 
 
ACCF/AHA Task Force on Practice Guidelines. Methodology Manual and Policies From the ACCF/AHA Task 739 
Force on Practice Guidelines. American College of Cardiology Foundation and American Heart Association, Inc. 740 
cardiosource.org. 2010. Available at: 741 
 http://assets.cardiosource.com/Methodology_Manual_for_ACC_AHA_Writing_Committees.pdf  742 
  743 
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Table 2. Criteria for literature search of the studies used during writing of the 744 
consensus document.   745 
Search query 746 
Minimized [All Fields] OR minimal [All Fields] OR miniaturized [All Fields] OR 747 
minimizing [All Fields] OR mini [All Fields] OR (minimally [All Fields] AND 748 
invasive [All Fields]) AND "extracorporeal circulation" [All Fields] OR minimized 749 
[All Fields] OR minimal [All Fields] OR miniaturized [All Fields] OR minimizing 750 
[All Fields] OR mini [All Fields] OR (minimally [All Fields] AND invasive [All 751 
Fields]) AND "cardiopulmonary bypass" [All Fields] OR "resting heart system" [All 752 
Fields] OR closed [All Fields] AND ("cardiopulmonary bypass" [MeSH Terms] OR 753 
"mecc" [All Fields]). 754 
29 
 
Table 3. Summary of the studies used for the consensus document.755 
30 
 
Author, journal date, 
(Ref.) 
Study type Type of 
procedure 
Patient groups Type of 
MiECC 
circuit 
Key results Comments 
Wiesenack, Artif 
Organs 2004, [10] 
Retrospective 
analysis 
CABG 485 MiECC/ 
485 CCPB 
type I - higher MAP and mean pump flow rate during in MiECC. 
- reduced frequency of vasoactive drug administration in 
MiECC patients (p<0.05). 
- maximum values of lactate concentration during bypass were 
significantly higher in CCPB. 
- minimum values of haemoglobin as an indicator of 
haemodilution were higher in MiECC patients, (p<0.05). 
- transfusion of packed red blood cells during surgery and 
during the complete perioperative course was significantly 
larger in CCPB (p<0.05).  
- 30-day mortality was similar between groups. 
-  incidence of postoperative complications was significantly 
higher in CCPB (p<0.05). 
First reported large series 
showing improved perfusion 
characteristics and clinical 
results 
Yilmaz, Interact 
Cardiovasc Thorac 
Surg 2010, [11] 
Prospective 
cohort study  
CABG+AVR 65 MiECC/ 
135 CCPB 
type III - reduced preoperative haemoglobin drop and higher 
haemoglobin at discharge in MiECC (p=0.03).  
- reduced blood products requirements in MiECC (p=0.004). 
- no differences were noted in pulmonary complications, 
neurological events or mortality. 
Feasibility study 
31 
 
Anastasiadis, 
Perfusion 2015, [12] 
Prospective 
cohort study 
various cardiac 
case-mix 
50 consecutive pts type IV - technical success 100% 
- 4% conversion rate from type III to type IV (modular 
MiECC) 
Clinical study on modular type 
IV MiECC in all types of 
cardiac surgery (feasibility and 
safety study) 
El-Essawi, Perfusion 
2011, [13] 
Multicentre 
RCT (six 
centres)  
CABG and/or 
AVR 
252 MiECC/ 
248 CCPB 
type IV - no operative mortality or device-related complications. 
- cardiotomy suction was necessitated by major bleeding in 10 
patients. 
- integration of a hard-shell reservoir was deemed necessary 
for air handling in one patient. 
- transfusion requirement (p=0.001), incidence of atrial 
fibrillation (p=0.03) and the incidence of major adverse events 
(p=0.02) were all in favour of the MiECC group. 
Focus on  modular type IV 
MIECC in CABG and/or AVR 
Fromes, Anaesthesia 
2011, [15] 
Retrospective 
analysis  
CABG 100 pts 300 IU/kg 
heparin/ 
68 pts 145 IU/kg 
heparin 
type II  - no thromboembolic events in either group 
- low-dose group had lower 
24-hour mean postoperative blood loss (p=0.001) and reduced 
rate of transfusion of allogeneic blood (p=0.01). 
Implementation of low-dose 
heparin protocol 
Nilson, Interact 
Cardiovasc Thorac 
Surg 2012, [17] 
RCT  CABG 27 low-dose heparin/ 
29 regular dose 
type II - four patients in the control group received a total of 10 units 
of packed red blood cells, and in the low-dose group no 
transfusions were given (p = 0.046). 
- no patient was reoperated because of bleeding. 
- ICU stay was significantly shorter in the low-dose group (p 
= 0.020), 
Feasibility of low-dose heparin 
32 
 
- patients in low-dose group were less dependent on oxygen 
on the first postoperative day (p =0.034), better mobilized (p = 
0.006) and had less pain (p=0.019). 
Anastasiadis, J 
Cardiothorac Vasc 
Anesth 2013, [23] 
RCT CABG 60 MiECC/ 
60 CCPB  
type II - incidence of fast-track recovery was significantly higher in 
patients undergoing MiECC (p=0.006). 
- MiECC was recognized as a strong  independent predictor of 
early recovery (p=0.011). 
- duration of mechanical ventilation and cardiac recovery unit 
stay were significantly lower in patients undergoing MiECC. 
- need for blood transfusion, duration of inotropic support, 
need for intra-aortic balloon pump, development of 
postoperative atrial fibrillation and renal failure were 
significantly lower in patients undergoing MiECC.  
Focus on fast-track protocols. 
Anastasiadis, 
Perfusion 2010, [26] 
RCT CABG 50 MiECC/ 
49 CCPB  
type I - less haemodilution (p=0.001),  markedly less haemolysis 
(p<0.001) and better preservation of the coagulation system 
integrity (p=0.01) favouring MiECC group.  
- less bank blood requirements were noted and a quicker 
recovery, as far as mechanical ventilation support and ICU 
stay are concerned, in MiECC group. 
Focus on haematological effects 
Haneya, ASAIO J 
2013, [27] 
Retrospective 
cohort analysis 
CABG 1073 MiECC/ 
872 CCPB  
type I -  postoperative creatine kinase and lactate levels were 
significantly lower in the MiECC group (p<0.001). 
-  no difference in postoperative blood loss between the 
groups.  
- intraoperative and postoperative transfusion requirements 
Focus on patients with 
preoperative anemia. 
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were significantly lower in the MiECC group (p<0.05).  
-  MiECC patients had lower incidences of postoperative acute 
renal failure, low cardiac output syndrome, shorter intensive 
care unit lengths of stay and reduced 30-day mortality 
(p<0.05). 
Zangrillo, J Thorac 
Cardiovasc Surg 
2010, [28] 
Meta-analysis 
(16 RCTs) 
CABG or AVR 803 MiECC/ 
816 CCPB 
 - MiECC was associated with significant reductions of 
neurologic damage (p=0.008), reduction in peak cardiac 
troponin (p< 0.001), and in the number of transfused patients 
(p<0.001). 
-  no difference in mortality was noted. 
Meta-analysis 
Anastasiadis, Int J 
Cardiol 2013, [18] 
Meta-analysis 
(24 RCTs) 
CABG or AVR 1387 MiECC/ 
1383 CCPB 
 - MiECC was associated with a significant decrease in 
mortality (p=0.02), in the risk of postoperative myocardial 
infarction (p=0.03) and reduced rate of neurologic events 
(p=0.08). 
- MiECC was associated with significantly reduced systemic 
inflammatory response, haemodilution, need for red blood cell 
transfusion, reduced levels of peak troponin release, incidence 
of low cardiac output syndrome, need for inotropic support, 
peak creatinine level, occurrence of postoperative atrial 
fibrillation, duration of mechanical ventilation and ICU stay. 
The largest meta-analysis 
Rahe-Meyer, Artif 
Organs 2010, [30] 
Prospective 
cohort study 
CABG 44 MiECC/ 
44 CCPB  
type I - aggregation decreased significantly in both groups as early 
as 30 min after the institution of CPB (p<0.05) and recovered 
within the first 24 h postoperatively, without reaching the 
preoperative level.  
- intraoperative aggregometry values reflected a significantly 
Focus on coagulation 
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more severe reduction of platelet function in CCPB group 
(p<0.01). 
El-Essawi, Perfusion 
2013, [31] 
Cohort study 
(Jehovah’s 
Witnesses) 
various cardiac 
case-mix  
29 pts 
22CABG +/- AVR 
 7 various case-mix 
type IV - mean decrease in hemoglobin was 2.1 ± 1.3 g/dl during 
cardiopulmonary bypass and 3.4 ±1.4 g/dl at discharge.  
- lowest postoperative hemoglobin level was 9.3 ±1.8 g/dl. 
Feasibility study on Jehovah’s 
Witnesses 
Fromes,  Eur J 
Cardiothorac Surg 
2002, [34] 
RCT CABG 30 MiECC/ 
30 CCPB  
type I - MiECC system allowed a reduced haemodilution (p<0.05). 
- mononuclear phagocytes dropped in a more important 
manner in CCPB group (p= 0.002) 
-  no significant release of IL-1b was observed in either group.  
- by the end of CPB, IL-6 levels were significantly lower in 
MiECC group (p=0.04), despite a higher monocyte count. 
- plasma levels of TNF-a increased significantly in CCPB 
group (p=0.002).  
-  neutrophil elastase release was significantly reduced in 
MiECC group (p=0.001). 
- platelet count remained at higher values with MiECC 
- β-thromboglobulin levels showed slightly lower platelet 
activation in the MiECC group (p =0.10).  
Focus on SIRS 
Immer, Ann Thorac 
Surg 2007, [36] 
Comparative 
cohort study 
CABG 1053 MiECC/ 
353 CCPB 
type I + 
smart 
suction 
- TnI was significantly lower in the MiECC group (p < 0.05). 
- incidence of AF was significantly reduced 
Feasibility/safety study 
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device in MiECC (p < 0.05). 
 - inflammatory markers (IL-6, SC5b-9) were lower in MiECC 
patients (p<0.05). 
- propensity score analysis confirmed faster recovery in 
MiECC patients and lower incidence of AF. 
Abdel-Rahman, Ann 
Thorac Surg 2005, 
[37] 
 RCT CABG 101 MiECC/ 
103 CCPB 
type II - intraoperative blood loss was significantly higher in CCPB 
group (p < 0.0001) as well as the need of fresh frozen plasma.  
- postoperative chest drainage did not differ significantly 
between groups.  
- one hour after CPB, PMNE as well as TCC were 
significantly lower in MiECC group (p<0.0001). 
Feasibility/safety study 
Ohata,  J Artif 
Organs 2007, [38] 
RCT CABG 15 MiECC/ 
15 CCPB  
type I - neutrophil elastase levels were lower in MiECC group at 
POD 1 and 2 (p=0.013) 
- IL-8 level were reduced in MiECC patients on POD 1 
(p=0.016).  
- intraoperative blood loss and transfusion volumes were 
significantly lower in MiECC group (p=0.012). 
Focus on SIRS 
Puehler,  Ann Thorac 
Surg 2009, [39] 
Comparative 
cohort study 
CABG 558 MiECC/ 
558 CCPB/ 
558 OPCAB  
type I - in-hospital mortality for elective and urgent/emergent 
patients was lower in the MiECC and OPCAB groups 
(p<0.05).  
- number of distal anastomoses was lowest in the OPCABG 
group, but comparable for MiECC and CCPB patients.  
Feasibility/safety study 
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- postoperative ventilation time, release of creatinine kinase, 
catecholamine therapy, drainage loss, and transfusion 
requirements were lower in the MiECC and OPCABG groups, 
whereas stay in the ICU was shorter only in the latter (p < 
0.05). 
Biancari, Heart 2009, 
[40] 
Meta-analysis 
(13 RCTs) 
CABG or AVR 562 MiECC/ 
599 CCPB 
 - MiECC was associated with reduced mortality during the 
immediate postoperative period, not reaching statistical 
significance ( p=0.25).  
- postoperative stroke rate was significantly 
lower in MiECC group ( p=0.05). 
- length of ICU stay  was similar in both groups (p=0.87) 
- MiECC was associated with a significantly lower amount of 
postoperative blood loss (p=0.0002) along with a higher 
platelet count 6 h after surgery (p=0.03). 
Meta-analysis 
Liebold, J Thorac 
Cardiovasc Surg 
2006, [42] 
RCT 
 
CABG 20 MiECC/ 
20 CCPB  
type I - CCPB group showed a highly significant reduction in both 
cerebral oxygenated hemoglobin and tissue oxygenation index 
from the start to the end of cardiopulmonary bypass (p<0.01).  
- the rate of decrease in cerebral oxygenated hemoglobin after 
aortic cannulation was faster in the CCPB group (p<0.001).  
- no significant changes with respect to cerebral oxygenated 
hemoglobin or tissue oxygenation index occurred MiECC 
group, except at the beginning of rewarming (p<0 .01). 
 - total embolic count, as well as gaseous embolic count, in the 
left and right median cerebral arteries was significantly lower 
Focus on cerebral protection 
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in MiECC group (all p<0.05).  
- postoperative bleeding was greater (p<0.05) and the 
transfusion rate was higher (p<0.05) in CCPB group. 
Zanatta, J 
Cardiothorac Vasc 
Anesth 2013, [43] 
Retrospective 
cohort 
CABG 19 MiECC (CABG)/ 
18  CCPB (AVR or 
MVR)/  
18 port-access MVR 
type I -  the number of solid microemboli and gaseous microemboli 
was significantly reduced in MiECC group (p<0.001). 
Focus on cerebral protection 
Camboni, ASAIO J 
2009, [44] 
RCT CABG 42 MiECC type I  
10 MiECC type II 
41 CCPB 
type I and II - MiECC resulted in reduced microbubble activity compared 
to CCPB (p=0.02).  
– Postoperative neuropsychological dysfunction (p=0.45), 
renal  dysfunction (p= 0.67), days of hospitalization (p=0.27), 
and 30 day-mortality (p=0.30) did not differ between groups. 
Focus on cerebral protection 
Anastasiadis, Heart 
2011, [45] 
RCT  CABG 29 MiECC / 
31 CCPB  
type I - MiECC was associated with improved cerebral perfusion 
during CPB. 
- Less patients operated on with MiECC experienced at least 
one episode of cerebral desaturation (p=0.04) with similar 
duration. 
- at discharge pts operated on with MiECC showed a 
significantly improved performance on complex scanning, 
visual tracking, focused attention and long-term memory. 
- at 3 months significantly improved performance was also 
evident on visuospatial perception, executive function, verbal 
Focus on neurocognitive 
outcome 
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working memory and short-term memory. 
- patients operated on with MiECC experienced a significantly 
lower risk of early cognitive decline both at discharge 
(p=0.03) and at 3-month evaluation (p<0.01). 
Reineke, Interact 
Cardiovasc Thorac 
Surg 2014, [46] 
Cohort study CABG 31 MiECC  type I + 
smart 
suction 
device 
MiECC does not adversely affect cognitive brain 
function after CABG.  
 
Focus on neurocognitive 
Gynaydin, Perfusion 
2009, [47] 
RCT CABG 20 MiECC/ 
20 CCPB 
type IV - serum IL-6 levels were significantly lower in the MiECC 
group (p<0.05). 
- C3a levels were significantly less in the Mini- 
CPB (p<0.01).  
- CK-MB levels in coronary sinus blood demonstrated well 
preserved myocardium in the MiECC group. 
- percentage expression of neutrophil CD11b/CD18 levels 
were significantly lower in the MiECC group (p<0.05).  
- no significant differences in air handling characteristics or 
free plasma hemoglobin levels in either circuit.  
- rSO2  measurements were significantly better in the MiECC 
group (p<0.05).  
- blood protein adsorption analysis of oxygenator 
membranes demonstrated a significantly increased amount of 
Focus on SIRS and 
haemodilution 
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microalbumin on CCPB fibers (p<0.05). 
Bennett, Perfusion 
2014, [48] 
Cohort study CABG and/or 
AVR 
39 MiECC 
41 CCPB 
type II - the average indexed bypass pump flow was significantly 
lower with MiECC with same average oxygen delivery. 
- pts in the CCPB group had a greater duration and severity of 
cerebral desaturation., which was significantly associated with 
low flows during CPB, whereas desaturation with MiECC was 
associated with low perioperative haemoglobin concentration. 
Focus on cerebral protection 
Panday, Interact 
Cardiovasc Thorac 
Surg 2009, [52] 
Prospective 
cohort study 
CABG 220 MiECC 
1143 CCPB 
109 OPCAB 
type II - operative mortality rates were comparable in all three 
groups. 
- the mean number of distal anastomoses was higher in 
MiECC and CCPB groups than OPCAB group (p=0.01). - 
arrhythmia occurred in 25% of the MiECC group, in 35.6% of 
the CCPB group (p=0.05) and in 21.7% of the OPCAB group. 
- 3% of the MiECC group suffered neurocognitive disorders 
perioperatively compared to 7% of the CCPB group (p=0.05) 
and 3% of the OPCAB group.  
- the median number of blood transfusions per patient was 
lower in MiECC and OPCAB groups (p<0.0001). 
Focus on blood transfusion 
Remadi, Am Heart J 
2006,  [53] 
RCT CABG 200 MiECC/ 
200 CCPB 
type I + 
suction 
device 
-  operative mortality rate similar between groups. 
- low-cardiac-output syndrome was reduced in MiECC group 
( p<0.001.).  
- inflammatory response was significantly reduced in  MiECC. 
C-reactive protein release postoperatively was significantly 
Feasibility/safety study 
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higher in CCPB group. 
- significantly higher decrease of haematocrit and 
haemoglobin rate in CCPB group. 
- intraoperative transfusion rate was reduced in MiECC group 
(p<0001).  
- patients in the CCPB group had significantly higher levels of 
postoperative blood creatinine and urea. 
Diez, ASAIO J 2009, 
[54] 
Retrospective 
observational 
study 
CABG 1685 MiECC / 
3046 CCPB 
type I - MiECC exerts beneficial haemodynamic effects but does not 
prevent AKI. 
- fewer patients developed a decline in eGFR <60 
mL/min/1.73 m2 in MiECC (p < 0.001).  
- the incidence of eGFR decrease by >50% did not differ 
(p=0.20).  
- temporary dialysis was reduced in MiECC group (p<0.001). 
- MiECC is renoprotective in the early postoperative period 
but cannot prevent AKI. 
Focus on renal function 
Huybregts, Ann 
Thorac Surg 2007, 
[55]  
RCT CABG 25 MiECC/ 
24 CCPB 
type II - MiECC was associated with attenuation of on-pump 
haemodilution, improved hemostatic status with 
reduced platelet consumption and platelet activation, 
decreased postoperative bleeding and minimized transfusion 
requirements.  
Focus on renal and intestinal 
function 
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- MiECC showed reduced leukocytosis and decreased urinary 
interleukin-6.  
- levels of urine NGAL were on average threefold 
lower and urinary intestinal fatty acid binding protein 
was 40% decreased in patients operated on MiECC. 
Capuano, Interact 
Cardiovasc Thorac 
Surg 2009, [56] 
Prospective 
cohort study 
CABG 30 MiECC/ 
30 CCPB 
type II - CCPB group showed a significant NGAL concentration 
increase from preoperative during the 1st   postoperative day 
(p<0.05).  
- no patient in MiECC group developed AKI.  
- renal function is better protected during MiECC as 
demonstrated by NGAL levels. 
Focus on renal injury 
Benedetto, Ann 
Thorac Surg 2009, 
[57] 
Prospective 
cohort study 
CABG 104 MiECC/ 
601 CCPB 
type II - overall incidence of AKI for patients undergoing MiECC 
was reduced (p=0.03).  
Focus on renal injury 
Bauer, J Extra Corpor 
Technol 2010, [58] 
RCT CABG 18 MiECC/ 
22 CCPB  
type II - MAP values were significantly higher in the MiECC group 
(p= 0 .002).  
- MiECC patients received significantly less norepinephrine (p 
=0.045). 
Focus on perfusion 
characteristics 
Skrabal, ASAIO J 
2007, [59] 
RCT CABG 30 MiECC/ 
30 CCPB  
type I - MiECC patients demonstrated significantly lower levels of 
TnT  at 6, 12, and 24 hours and CK-MB levels at 6 and 12 
hours . 
Focus on myocardial protection 
Van Boven, Eur J RCT CABG 10 MiECC type I - markers of myocardial oxidative stress or activity were Focus on myocardial protection 
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Cardiothorac Surg 
2008, [60] 
10 CCP 
10 OPCAB 
significantly lower in MiECC group compared to CCPB and 
OPCAB (p=0.04 and 0.03 respectively). 
Nguygen, Mol Cell 
Biochem 2014, [61]  
RCT CABG 13 MiECC/ 
13 CCPB 
(intermittent cross-
clamp fibrillation) 
type III - the overall cardiac injury was significantly lower 
in the MiECC group as measured by TnT (p=0.02). 
Focus on myocardial protection 
Van Boven, Eur J 
Anaesthesiol 2013, 
[62] 
RCT  CABG 20 MiECC 
20 CCP 
20 OPCAB 
type I - MiECC group showed significantly lower median TnT levels 
compared with CCPB and OPCAB (p<0.003).  
- HFABP, IFABP and a-GST levels were significantly higher 
during CCPB compared with OPCAB and MiECC (p<0.009).  
- there was a trend towards higher median CC16 levels in the 
CCPB group (p<0.07). 
Focus on end-organ protection 
Prasser, Perfusion 
2007, [63] 
RCT CABG 10 MiECC/ 
10 CCPB  
type I - liver function as measured by disappearance rate of 
indocyanine green was markedly increased after cardiac 
surgery without significant differences between groups. 
Focus on liver function 
Donndorf, J Thorac 
Cardiovasc Surg 
2012, [64] 
RCT CABG 20 MiECC/ 
20 CCPB 
type I - there is an impairment of microvascular perfusion 
during CCPB (p=0.034). 
 - changes in functional capillary density indicate a faster 
recovery of the microvascular perfusion in MiECC during the 
reperfusion period (p=0.017). 
Focus on microvascular 
perfusion 
Haneya, Eur J 
Cardiothorac Surg 
Retrospective 
cohort study 
CABG 105 MiECC / type I - CK levels were significantly lower 6 h after surgery in the 
MiECC group (p < 0.05). 
Focus on high-risk patients. 
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2009, [65]  139 CCPB 
(high-risk patients) 
- need of red blood cell transfusion was significantly lower 
after MiECC surgery (p < 0.05). 
- 30-day mortality was significantly lower in the MiECC 
group (p<0.01).  
Kolat, J Cardiothorac 
Surg 2014, [66] 
Retrospective 
cohort analysis 
CABG 1137 MiECC / 
1137 CCPB 
type I - postoperative requirement of renal replacement therapy 
(p=0.01), respiratory insufficiency (p=0.004) and incidence of 
low cardiac output syndrome (p= 0.003) were significantly 
increased in patients with CCPB. 
Focus on clinical outcome. 
Ried, J Cardiothorac 
Surg 2013, [67] 
Propensity score 
analysis 
emergency 
CABG 
146 MiECC / 
175 CCPB  
type I - 30-day mortality was reduced in patients with MiECC 
(p=0.03).  
- ICU stay (p=0.70), hospital stay (p=0.40) and postoperative 
low cardiac output syndrome (p=0.83) did not show 
significant differences between both groups.  
Focus on emergency CABG 
Koivisto, Perfusion 
2010, [68] 
Propensity score 
analysis 
CABG 89 MiECC / 
147 CCPB  
type II - stroke rate was significantly higher among CCPB patients 
(p=0.026). 
-  in-hospital mortality, combined adverse end-point rate, 
postoperative bleeding and need for transfusion were 
statistically insignificant in the study groups. 
Focus on high-risk patients 
Anastasiadis, Int J 
Cardiol 2013, [69] 
Cost-analysis  CABG 1026 MiECC/ 
1023 CCPB 
 - in terms of total therapy cost per patient the comparison 
favored MiECC in all countries. 
-  it was associated with a reduction of €635 in Greece, €297 
in Germany, €1590 in the Netherlands and €375 in 
Switzerland.  
- in terms of effectiveness, the total life-years gained were 
Focus on cost-effectiveness 
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slightly higher in favor of MiECC. 
Fernandes, Perfusion 
2010, [70] 
Retrospective 
cohort study 
CABG 15 MiECC type II - using lower than predicted flows, adequate perfusion was 
provided. 
Focus on perfusion 
characteristics 
Puehler, Thorac 
Cardiovasc Surg 
2010, [75] 
Retrospective 
comparative 
cohort study 
CABG 119 MiECC / 
119 CCPB 
type I - MiECC patients had a tendency towards a lower 30-day 
mortality rate, a better postoperative renal function and 
reduced ventilation times. 
-  CPB time and postoperative high-dose inotropic support 
were significantly lower in the MiECC group. 
- ICU and hospital stay were comparable between the two 
groups. 
Focus on high-risk patients 
a-GST: a-Glutathione S-Transferase AF: Atrial fibrillation; AKI: Acute Kidney Injury; AVR; Aortic Valve Replacement; CABG: Coronary Artery Bypass Grafting; 
CCPB: Conventional Cardiopulmonary Bypass; CPB: Cardiopulmonary Bypass; HFABP: Heart type Fatty Acid Binding Protein; ICU: Intensive Care Unit; IFABP: 
Intestinal type Fatty Acid Binding Protein; IL: Interleukin; MAP: Mean Arterial Pressure; MiECC: Minimal invasive Extracorporeal Circulation; MVR: Mitral Valve 
Replacement; NGAL: Neutrophil Gelatinase-Associated Lipocalin; OPCAB: Off-Pump Coronary Artery Bypass grafting; pts: patients; POD: Postoperative Day; RCT: 
Randomized Controlled Trial; SIRS: Systemic Inflammatory Response Syndrome; TNF: Tumor Necrosis Factor; TnT: Troponin-T; TnI: Troponin I 
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Table 4. Summary of statements endorsed by the Expert Committee 
 
 
Recommendation 
 
Minimal invasive extracorporeal circulation (MiECC) refers to a combined 
strategy of surgical approach, anaesthesiological and perfusion management 
and should not be limited to the CPB circuit alone.  
 
In order to be characterized as MiECC, the main components of the system 
must include: closed circuit; biologically inert blood contact surfaces; 
reduced priming volume; centrifugal pump; membrane oxygenator; heat 
exchanger; cardioplegia system; venous bubble trap/venous air removing 
device; shed blood management system. 
 
Additional components that can be integrated to a MiECC system are: 
pulmonary artery vent; pulmonary vein vent; aortic root vent; soft bag / 
soft-shell reservoir; hard-shell reservoir (modular systems); regulated smart 
suction device; arterial line filtration. 
  
46 
 
Table 5. Summary of evidence-based practice guidelines 
 
Recommendation Level 
of Evidence 
References 
Class I   
MiECC systems reduce haemodilution and better preserve haematocrit as 
well as reduce postoperative bleeding and the need for RBC transfusion. 
A 18,26,28 
MiECC systems reduce the incidence of postoperative atrial fibrillation. A 13,18,23,28 
MiECC systems preserve renal function. A 18,55 
MiECC is associated with improved myocardial protection A 18,59,60,61 
   
Class IIA   
Inflammatory response assessed by specific inflammatory markers is 
attenuated with use of MiECC. 
B 34,36,37,38 
MiECC systems can reduce cerebral gaseous microembolism and preserve 
neurocognitive function.  
B 18,42,43,44,45,46 
MiECC exerts a subclinical protective effect on end-organ function (lung, 
liver, intestine) which is related to enhanced recovery of microvascular organ 
perfusion. 
B 55,62,63,64 
   
Class IIB   
   
Within a MiECC strategy, less thrombin generation may permit reduced 
heparin dose targeted to shorter ACT times. When such a strategy is 
followed, individual heparin dose should be determined using heparin dose-
response monitoring systems. 
B 14,15,17,20 
MiECC appears to offer survival benefit in terms of lower 30-day mortality 
after CABG procedures. 
B 18,65,66,67 
 
Use of short-acting opioids in combination with propofol or volatile 
anaesthetics, and hypnotic effect monitoring by processed EEG, is 
recommended for induction and maintenance of anaesthesia for MiECC-
C 21,22,23,24,25 
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based surgery. TEE findings pertinent to institutional management of MiECC 
should be communicated during the preoperative surgical safety time out. 
ACT: Activated Clotting Time; CABG: Coronary Artery Bypass Grafting; EEG: Electroencephalogram; 
MiECC: Minimal Invasive Extracorporeal Circulation; RBC: Red Blood Cells.  
